Latest Posts
Are gene-editing therapies patentable? A WIPO side event investigates.
On 6 December, Knowledge Ecology International (KEI) organised an interesting panel on the patentability of new gene- and cell-based medical therapies, as a side...
New Database Documents the Power of TRIPS Flexibilities
Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS...
New Tool Maps Use of TRIPS Flexibilities for Public Health
Flexibilities were essential in providing access to HIV medicines; today, the need for access to other essential treatments is driving their uptake
27 NOVEMBER 2018: Medicines Law & Policy today launches a new tool demonstrating how key...
WIPO and pharma industry launch global medicines patent database
On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...
Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening
Today health insurance company Menzis announced that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
This work is licensed under